{"id":"oxycodone-naltrexone-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL656","moleculeType":"Small molecule","molecularWeight":"315.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxycodone binds to mu-opioid receptors to produce analgesia and pain relief. Naltrexone, an opioid antagonist, is included in the formulation to counteract some opioid side effects and theoretically reduce the rewarding properties that contribute to misuse. The combination aims to maintain analgesic efficacy while improving the safety and tolerability profile compared to oxycodone alone.","oneSentence":"Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:49.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe chronic pain"}]},"trialDetails":[{"nctId":"NCT05043766","phase":"PHASE1","title":"Evaluation of Oral PF614 Relative to OxyContin (PF614-102)","status":"COMPLETED","sponsor":"Ensysce Biosciences","startDate":"2021-09-08","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT01746901","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":81},{"nctId":"NCT01677065","phase":"","title":"A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT01456507","phase":"PHASE1","title":"Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01775189","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-02","conditions":"Healthy","enrollment":45},{"nctId":"NCT02401750","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery","status":"COMPLETED","sponsor":"Elite Laboratories, Inc","startDate":"2015-06","conditions":"Pain","enrollment":163},{"nctId":"NCT02117583","phase":"PHASE1","title":"Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":34},{"nctId":"NCT02165930","phase":"PHASE1","title":"Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-07","conditions":"Healthy","enrollment":17},{"nctId":"NCT02089295","phase":"PHASE1","title":"Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT02059915","phase":"PHASE1","title":"Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2014-04","conditions":"Healthy","enrollment":134},{"nctId":"NCT01717027","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-11","conditions":"Healthy","enrollment":19},{"nctId":"NCT01552850","phase":"PHASE1","title":"Pharmacokinetics And Relative Bioavailability Study Of Oxycodone","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-04","conditions":"Pain","enrollment":18},{"nctId":"NCT01924676","phase":"PHASE1","title":"Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2013-08","conditions":"Healthy","enrollment":18},{"nctId":"NCT01552863","phase":"PHASE1","title":"A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers","status":"COMPLETED","sponsor":"Pain Therapeutics","startDate":"2012-03","conditions":"Pain","enrollment":21},{"nctId":"NCT01825447","phase":"PHASE1","title":"A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07","conditions":"Healthy","enrollment":89},{"nctId":"NCT01677039","phase":"PHASE1","title":"Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oxycodone Naltrexone (b)","genericName":"Oxycodone Naltrexone (b)","companyName":"Elite Laboratories, Inc","companyId":"elite-laboratories-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential. Used for Moderate to severe chronic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}